Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

49.14 USD

Average target price

56.2 USD

Spread / Average Target

+14.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-4.23%	99.59B
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+25.38%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ABBVIE INC.	+8.34%	297B
ASTRAZENECA PLC	+6.13%	215B
NOVARTIS AG	+2.93%	210B
ROCHE HOLDING AG	-7.65%	200B
PFIZER, INC.	-8.79%	149B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-22 pm EDT			5-day change	1st Jan Change
49.14 ^USD	+0.43%		+1.30%	-4.23%

Apr. 22	Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	RE
Apr. 22	Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies	MT

Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies	Apr. 22	MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares	Apr. 22	RE
Bristol Myers signs supply agreement with Cellares	Apr. 22	CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies	Apr. 22	RE
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies	Apr. 22	CI
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	Apr. 22	MT
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	Apr. 18	MT
Pathios Therapeutics Limited announced a financing transaction	Apr. 17	CI
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors	Apr. 16	CI
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	Apr. 12	MT
TORL BioTherapeutics LLC announces tranche update	Apr. 09	CI
Bristol Myers: cancer treatment results	Apr. 09	CF
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	Apr. 09	MT
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	Apr. 08	CI
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta...	Apr. 08
Bristol Myers: new data on schizophrenia	Apr. 08	CF
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies	Apr. 06	RE
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	Apr. 05	MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	Apr. 05	DJ
Bristol Myers: FDA approves Abecma in multiple myeloma	Apr. 05	CF